Since hemophilia was discovered, it has been accepted as a male disease. No one questions that a man is struggling with hemophilia. A man with a bleeding disorder living in a developed country is rarely denied access to healthcare. When he receives a diagnosis, he is told that…
Search results for:
Starting factor VIII (FVIII) preventive therapy before the age of 2.5 years improves joint outcomes in young adults with hemophilia A compared to starting treatment later in childhood, a clinical trial shows. The study, “ Young adult outcomes of childhood prophylaxis for severe hemophilia A:…
Should regulatory authorities agree with favorable results from Genentech’s ongoing Phase 3 studies of Hemlibra (emicizumab-kxwh),  hemophilia A patients may have a treatment they can use regardless of inhibitor status, with a choice of three dosing schedules that might better match their lifestyle and preferences. “The ultimate goal for…
Kovaltry (octocog alfa) is effective and safe as a preventive treatment for children with hemophilia A, a European real-world study reports. The study, “Real-world evidence on Kovaltry (81-8973) in children with moderate or severe hemophilia A in Europe: a…
BrightInsight has launched a web-based dosing calculator to help physicians select the correct loading and maintenance dose of the treatment Hemlibra according to the body measurements of their patients with hemophilia A. The dosing calculator, launched with the support of Hemlibra’s manufacturer, Roche, will support the…
Hemophilia A patients who receive replacement therapies of factor VIII often develop inhibitors against factor concentrates which hinders the effectiveness of the therapy, increases disability, and reduces quality of life. Although immune tolerance induction (ITI) can reduce inhibitors against factor VIII concentrates, the study “Long-term course of…
Shire and Rani Therapeutics have partnered to investigate the use of oral Rani Pill technology as the carrier system for clotting factor VIII in hemophilia A patients. As part of Shire’s commitment, the Irish pharmaceutical company made an equity investment in Rani. Under the agreement — whose terms weren’t…
The U.S. Food and Drug Administration (FDA) has accepted Bayer’s Biologics License Application (BLA) filing for BAY94-9027 to treat hemophilia A in adolescents starting at age 12, and in adults. A BLA is a marketing application that covers biological products, as opposed to chemically synthesized ones, and its…
Bayer’s Jivi safely and effectively prevents bleeds during and after minor surgery in children, adolescents, and adults with severe hemophilia A, according to interim data from the Phase 2/3 PROTECT VIII and the Phase 3 PROTECT VIII Kids clinical trials. Most of the included patients were on…
Treatment with Esperoct (turoctocog alfa pegol) effectively prevents bleeding during and after major surgery in patients with severe hemophilia A, final data from a Phase 3 trial show. The study, “…